Fig. 5

Diagnostic performance of the models and methylation levels in the model validation cohort (n = 105). A Methylation levels of the final 20 selected biomarkers in the model validation cohort (*Wilcoxon rank-sum test p value < 0.05). B ROC curve analysis and AUC for the three models evaluated for CRC screening, derived by leave-one-out cross-validation (GALNT9: CG3; UPF3A: CG15; WARS: CG5; and LDB2: CG24). The red dots indicate the sensitivity and specificity values for the best cutoffs based on the Youden index method. C Serum methylation levels of CG3-GALNT9, CG15-UPF3A, CG5-WARS, and CG24-LDB2 in the model validation cohort (n = 105), and in lung, breast, kidney, prostate, and ovarian cancer cases (n = 16). D Methylation levels and classification performance (ROC curve) of the SEPT9 promoter. The red dot indicates the best sensitivity and specificity values (Youden index). E Comparison of methylation levels between matched serum and plasma samples. AUC: area under the curve; NN: no neoplasia; AA: advanced adenomas; and CRC: colorectal cancer